---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-263617"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:46:55.913740+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Heron Q3 net revenue $38.2M, acute care +67% YoY, FY guidance reaffirmed

## Summary
- Q3 net revenue $38.2M (+16.5% YoY); YTD $114.3M.
- ZYNRELEF net revenue $9.3M (+49% YoY); APONVIE $3.0M (+173% YoY).
- FY 2025 guidance reaffirmed: net revenue $153-163M, adj. EBITDA $9-13M.
- J-code for ZYNRELEF effective Oct 1, 2025; VAN transition complete.
- Cash and investments $55.5M as of Sept 30, 2025.

## SEC filing metadata
- accession: 0001193125-25-263617
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312525263617/0001193125-25-263617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312525263617/hrtx-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-263617
- JSON: https://secwatch.observer/filing/0001193125-25-263617.json
- Plain text: https://secwatch.observer/filing/0001193125-25-263617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.